According to The Fly, cowen & Co. analyst Ritu Baral maintained a Buy rating on Ovid Therapeutics Inc (NASDAQ: OVID) yesterday. The company’s shares opened today at $5.21, close to its 52-week low of $5.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 24.2% and a 46.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
Currently, the analyst consensus on Ovid Therapeutics Inc is a Moderate Buy with an average price target of $20.
See today’s analyst top recommended stocks >>
Based on Ovid Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $12.94 million. In comparison, last year the company had a GAAP net loss of $9.36 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ovid Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing impactful medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
